Hang Lung Group Limited
Hang Lung Group Limited (0010.HK) Financial Performance & Income Statement Overview
Explore the financials of Hang Lung Group Limited (0010.HK), including yearly and quarterly data on income, cash flow, and balance sheets.
Hang Lung Group Limited (0010.HK) Income Statement & Financial Overview
Analyze Hang Lung Group Limited’s 0010.HK earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 |
|---|---|---|---|---|
| Revenue | $5.38B | $6.51B | $5.35B | $5.53B |
| Cost of Revenue | $2.17B | $2.77B | $1.60B | $1.49B |
| Gross Profit | $3.21B | $3.75B | $3.76B | $4.03B |
| Gross Profit Ratio | $0.60 | $0.58 | $0.70 | $0.73 |
| R&D Expenses | $0.00 | $0.00 | $52.00M | $50.00M |
| SG&A Expenses | $326.00M | $346.00M | $341.00M | $339.00M |
| Operating Expenses | $326.00M | $3.86B | $2.29B | $1.62B |
| Total Costs & Expenses | -$2.49B | $3.86B | $1.94B | $1.83B |
| Interest Income | $20.00M | $40.00M | $52.00M | $50.00M |
| Interest Expense | $0.00 | $0.00 | $1.09B | $897.00M |
| Depreciation & Amortization | $71.00M | -$3.41B | $42.00M | $46.00M |
| EBITDA | $2.96B | -$1.76B | $3.46B | $3.74B |
| EBITDA Ratio | $0.55 | -$0.27 | $0.65 | $0.68 |
| Operating Income | $2.89B | $3.41B | $3.42B | $3.69B |
| Operating Income Ratio | $0.54 | $0.52 | $0.64 | $0.67 |
| Other Income/Expenses (Net) | -$944.00M | -$1.26B | -$656.00M | -$8.00M |
| Income Before Tax | $1.95B | $2.15B | $2.76B | $3.69B |
| Income Before Tax Ratio | $0.36 | $0.33 | $0.52 | $0.67 |
| Income Tax Expense | $660.00M | $756.00M | $812.00M | $847.00M |
| Net Income | $725.00M | $888.00M | $1.13B | $1.68B |
| Net Income Ratio | $0.13 | $0.14 | $0.21 | $0.30 |
| EPS | $0.53 | $0.65 | $0.83 | $1.24 |
| Diluted EPS | $0.53 | $0.65 | $0.83 | $1.24 |
| Weighted Avg Shares Outstanding | $1.36B | $1.37B | $1.36B | $1.36B |
| Weighted Avg Shares Outstanding (Diluted) | $1.36B | $1.36B | $1.36B | $1.36B |
Over the last four quarters, Hang Lung Group Limited's revenue moved from $5.53B in Q2 2023 to $5.38B in Q4 2024. Operating income in Q4 2024 was $2.89B, with a strong operating margin of 54%. Despite fluctuations in R&D and SG&A expenses, EBITDA for Hang Lung Group Limited remained robust at $2.96B, reflecting operational efficiency. Net income dropped to $725.00M, with an EPS of $0.53. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan